Answers are grounded in this paper and cite their sources.
Investigation reveals HuGLP-1-loaded bilosomes significantly improve glycemic control in T2DM, suggesting a new therapeutic pathway.
Type 2 diabetes mellitus (T2DM) is the most devastating disease and it necessitates therapeutic intervention for its effective management. Human Glucagon-like peptide-1 (HuGLP-1) is the potential candidate in the treatment of T2DM; however, it limits its utilization owing to its solubility and stability issues. The current investigation aims to develop HuGLP-1-loaded bilosomes as a novel strategy for managing T2DM. The HuGLP-1-loaded bilosomes were developed and characterized for its size, polydispersity index, surface charge, entrapment efficiency, morphology, drug release, and stability studies. The hypoglycemic potential and histopathology were studied using streptozotocin-induced diabetic rats. Bilosomes were successfully developed with size of 197.96 ± 0.61 nm, polydispersity index 0.191 ± 0.01 and surface charge of -27.63 ± 1.02 mV. The in vitro release of HuGLP-1-loaded bilosomes showed sustained release profile of HuGLP-1 extending over 24-h period, in compared to plain HuGLP-1 solution, and follows Weibull release kinetics model. The HuGLP-1-loaded bilosomes revealed significant hypoglycemic effects in comparison to both oral and subcutaneous HuGLP-1 solutions. Histopathological evaluations revealed that HuGLP-1-loaded bilosomes showed promising improvement in histology of liver, kidney, and intestines. The HuGLP-1-loaded bilosomes were found to be potential therapeutic approach for the effective management of T2DM.
No takes yet. Share an insight, caveat, or question.
Vidhate et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: